共 32 条
Transcatheter Aortic Valve Implantation for Pure Severe Native Aortic Valve Regurgitation
被引:249
作者:
Roy, David A.
[1
]
Schaefer, Ulrich
[2
]
Guetta, Victor
[3
]
Hildick-Smith, David
[4
]
Moellmann, Helge
[5
]
Dumonteil, Nicholas
[6
]
Modine, Thomas
[7
]
Bosmans, Johan
[8
]
Petronio, Anna Sonia
[9
]
Moat, Neil
[10
]
Linke, Axel
[11
]
Moris, Cesar
[12
]
Champagnac, Didier
[13
]
Parma, Radoslaw
[14
]
Ochala, Andrzej
[14
]
Medvedofsky, Diego
[3
]
Patterson, Tiffany
[10
]
Woitek, Felix
[11
]
Jahangiri, Marjan
[1
]
Laborde, Jean-Claude
[1
]
Brecker, Stephen J.
[1
]
机构:
[1] St George Hosp, Dept Cardiol & Cardiothorac Surg, London SW17 0QT, England
[2] Gen Hosp St Georg, Dept Cardiol, Hamburg, Germany
[3] Chaim Sheba Med Ctr, Dept Cardiol, Ramat Gan, Israel
[4] Brighton & Sussex Univ Hosp, Sussex Cardiac Ctr, Brighton, E Sussex, England
[5] Kercoff Heart & Thorax Ctr, Bad Nauheim, Germany
[6] CHU Rangueil, Dept Cardiol, F-31054 Toulouse, France
[7] Hop Cardiol, F-59037 Lille, France
[8] Univ Antwerp Hosp, Dept Cardiol, Antwerp, Belgium
[9] Azienda Osped Univ Pisana, Cardiothorac Dept, Pisa, Italy
[10] Royal Brompton Hosp NHS Trust, Dept Cardiothorac Surg, London, England
[11] Leipzig Heart Ctr, Leipzig, Germany
[12] Hosp Univ Cent Asturias, Dept Cardiol & Cardiothorac Surg, Asturias, Spain
[13] Tonkin Clin, Dept Cardiol, Villeurbanne, France
[14] Med Univ Silesia, Dept Cardiol & Cardiothorac Surg, Katowice, Poland
关键词:
native aortic valve regurgitation;
transcatheter aortic valve implantation;
HIGH-RISK PATIENTS;
COREVALVE REVALVING SYSTEM;
VALVULAR HEART-DISEASE;
COMPUTED-TOMOGRAPHY;
CLINICAL-PRACTICE;
FOLLOW-UP;
STENOSIS;
REPLACEMENT;
PROSTHESIS;
REGISTRY;
D O I:
10.1016/j.jacc.2013.01.018
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Objectives This study sought to collect data and evaluate the anecdotal use of transcatheter aortic valve implantation (TAVI) in pure native aortic valve regurgitation (NAVR) for patients who were deemed surgically inoperable Background Data and experience with TAVI in the treatment of patients with pure severe NAVR are limited. Methods Data on baseline patient characteristics, device and procedure parameters, echocardiographic parameters, and outcomes up to July 2012 were collected retrospectively from 14 centers that have performed TAVI for NAVR. Results A total of 43 patients underwent TAVI with the CoreValve prosthesis (Medtronic, Minneapolis, Minnesota) at 14 centers (mean age, 75.3 +/- 8.8 years; 53% female; mean logistic EuroSCORE (European System for Cardiac Operative Risk Evaluation), 26.9 +/- 17.9%; and mean Society of Thoracic Surgeons score, 10.2 +/- 5.3%). All patients had severe NAVR on echocardiography without aortic stenosis and 17 patients (39.5%) had the degree of aortic valvular calcification documented on CT or echocardiography. Vascular access was transfemoral (n = 35), subclavian (n = 4), direct aortic (n = 3), and carotid (n = 1). Implantation of a TAVI was performed in 42 patients (97.7%), and 8 patients (18.6%) required a second valve during the index procedure for residual aortic regurgitation. In all patients requiring second valves, valvular calcification was absent (p = 0.014). Post-procedure aortic regurgitation grade I or lower was present in 34 patients (79.1%). At 30 days, the major stroke incidence was 4.7%, and the all-cause mortality rate was 9.3%. At 12 months, the all-cause mortality rate was 21.4% (6 of 28 patients). Conclusions This registry analysis demonstrates the feasibility and potential procedure difficulties when using TAVI for severe NAVR. Acceptable results may be achieved in carefully selected patients who are deemed too high risk for conventional surgery, but the possibility of requiring 2 valves and leaving residual aortic regurgitation remain important considerations. (J Am Coll Cardiol 2013;61:1577-84) (c) 2013 by the American College of Cardiology Foundation
引用
收藏
页码:1577 / 1584
页数:8
相关论文